Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).

Johanna C.  Bendell

Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Fusion Pharmaceuticals (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Kyn therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst)

Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); Arcus Biosciences (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); AtlasMedx (Inst); Bayer (Inst); BeiGene (Inst); Bellicum Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); Elicio Therapeutics (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Evelo Therapeutics (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); Hutchison MediPharma (Inst); IGM (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Loxo/Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); NeoImmuneTech (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Novocure (Inst); Numab (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Regeneron (Inst); Relay Therapeutics (Inst); Repare Therapeutics (Inst); Revolution Medicines (Inst); Rgenix (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Shattuck Labs (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Treadwell Therapeutics (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst); Zymeworks (Inst)

Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical

Patricia  LoRusso

Honoraria - Five Prime Therapeutics

Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; Bayer; Black Diamond Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Molecular Templates; Molecular Templates; Pfizer; QED Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis

Research Funding - Genentech (Inst)

Travel, Accommodations, Expenses - Genentech

Michael J.  Overman

Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Gritstone Bio; Janssen; Janssen; MedImmune; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals

Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche

Anne M.  Noonan

Consulting or Advisory Role - Eisai; Exelixis; Helsinn Healthcare; QED Therapeutics

Dong-Wan  Kim

Research Funding - Alpha Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Hanmi (Inst); Janssen (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst)

Travel, Accommodations, Expenses - Amgen; Daiichi Sankyo

John  Strickler

Consulting or Advisory Role - AstraZeneca

Research Funding - AstraZeneca (Inst)

Sang-We  Kim

No Relationships to Disclose

Stephen John  Clarke

Employment - GenesisCare

Stock and Other Ownership Interests  - GenesisCare

Honoraria - Tetra Health

Consulting or Advisory Role - AllVascular; AstraZeneca/MedImmune; AstraZeneca/MedImmune; Bayer; Ipsen; Merck

Speakers' Bureau - Merck; Novartis/Ipsen

Travel, Accommodations, Expenses - Bristol-Myers Squibb; MedLab

Thomas J.  George

Consulting or Advisory Role - Tempus

Research Funding - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Seagen (Inst); Tesaro (Inst)

Peter S.  Grimison

Research Funding - ASLAN Pharmaceuticals (Inst); Boston Biomedical (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Janssen-Cilag (Inst); Medimmune; MSD (Inst); Pfizer (Inst); Pfizer (Inst); QED Therapeutics (Inst); Specialised Therapeutics (Inst); Tigermed (Inst); Tilray (Inst)

Minal A.  Barve

Employment - Texas Oncology

Stock and Other Ownership Interests  - Texas Oncology

Research Funding - Mary Crowley Research Center, Dallas Texas

Manik A.  Amin

No Relationships to Disclose

Jayesh  Desai

Consulting or Advisory Role - Amgen (Inst); Bayer; BeiGene; Eisai; Pierre Fabre

Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Lilly (Inst); Novartis (Inst); Roche (Inst)

Trisha  Wise-Draper

Stock and Other Ownership Interests  - High Enroll

Honoraria - Physicans' Education Resource

Consulting or Advisory Role - Exicure; Rakuten Medical; Shattuck Labs

Research Funding - AstraZeneca; Bristol-Myers Squibb; Caris Life Sciences; GlaxoSmithKline; Merck

Travel, Accommodations, Expenses - AstraZeneca; Bexion; Bristol-Myers Squibb; Caris Life Sciences; Lilly; Merck; Tesaro

Zachary  Cooper

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Nairouz  Elgeioushi

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Nancy Kathryn  Mueller

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Rakesh  Kumar

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Kevin YuFeng  Wu

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Sandip Pravin  Patel

No Relationships to Disclose